SOLO-1 Lynparza Data In First-Line Ovarian Cancer Seen Boosting AstraZeneca's PARP Edge
In SOLO-1 Lynparza becomes the first PARP to show benefit in first-line BRCA-mutated ovarian cancer.
In SOLO-1 Lynparza becomes the first PARP to show benefit in first-line BRCA-mutated ovarian cancer.